Ostalis

At the International Mneopause Society meeting in June 2018, many therapies were presented that aren't yet available in Canada. One such treatment is an oral tablet for menopausal women experiencing moderate to severe pain with intercourse. This tablet is called ospemifene (Ostalis) and is swallowed once daily. Improvement can begin as early as two weeks into therapy. This medication is classified as a selective estrogen receptor modulator. This means that it stimulates estrogen receptors in some tissues and blocks estrogen receptors in others. It is not an actual estrogen but a synthetic product. The advantage of this treatment is that it stimulates tissue in the vagina while not stimulating the breast. It is not a treatment for hot flashes and night sweats. It is expected that this product will be in Canada in 2019 and may have some advantages over topical creams and vaginal tablets for women uncomfortable or unable to apply or insert products in this area. Stay tuned...